BACKGROUND: To clarify which types of cells produce interferon-gamma-inducible protein 10 (IP-10) and whether IP-10 is associated with the development of ulcerative colitis (UC), we investigated IP-10 production in UC patients. METHODS: Serum IP-10 levels were measured using enzyme-linked immunosorbent assay in 29 patients with active and 21 with inactive UC and in 20 controls. The production of IP-10 by granulocytes and monocytes adsorbed to G-1 beads was examined. In 21 active UC patients treated with granulocyte and monocyte/macrophage adsorptive apheresis (GMA), serum IP-10 levels were measured before and after treatment. IP-10-positive cells in UC mucosa were also examined immunohistochemically using tissues obtained by surgical resection and colonoscopic biopsies. RESULTS: Serum IP-10 levels in active UC patients were significantly higher than those in inactive patients, although even in the latter the levels were increased compared with those in controls. IP-10 production by granulocytes and monocytes in active UC patients was significantly higher than that in controls. Furthermore, the number of IP-10-positive cells was elevated in the colonic mucosa of patients with active UC, and one of the main subpopulations of IP-10-positive cells was granulocytes. Serum IP-10 levels decreased following GMA treatment in responders, but not in nonresponders. Interestingly, serum IP-10 levels before GMA were higher in responders than in nonresponders. In parallel with the serum levels, IP-10-positive cells also decreased following GMA treatment. CONCLUSIONS: Serum IP-10 levels reflected UC disease activity, and the source of IP-10 was granulocytes and monocytes. Furthermore, serum IP-10 levels may be a marker for the responsiveness of patients to GMA treatment.
BACKGROUND: To clarify which types of cells produce interferon-gamma-inducible protein 10 (IP-10) and whether IP-10 is associated with the development of ulcerative colitis (UC), we investigated IP-10 production in UC patients. METHODS: Serum IP-10 levels were measured using enzyme-linked immunosorbent assay in 29 patients with active and 21 with inactive UC and in 20 controls. The production of IP-10 by granulocytes and monocytes adsorbed to G-1 beads was examined. In 21 active UC patients treated with granulocyte and monocyte/macrophage adsorptive apheresis (GMA), serum IP-10 levels were measured before and after treatment. IP-10-positive cells in UC mucosa were also examined immunohistochemically using tissues obtained by surgical resection and colonoscopic biopsies. RESULTS: Serum IP-10 levels in active UC patients were significantly higher than those in inactive patients, although even in the latter the levels were increased compared with those in controls. IP-10 production by granulocytes and monocytes in active UC patients was significantly higher than that in controls. Furthermore, the number of IP-10-positive cells was elevated in the colonic mucosa of patients with active UC, and one of the main subpopulations of IP-10-positive cells was granulocytes. Serum IP-10 levels decreased following GMA treatment in responders, but not in nonresponders. Interestingly, serum IP-10 levels before GMA were higher in responders than in nonresponders. In parallel with the serum levels, IP-10-positive cells also decreased following GMA treatment. CONCLUSIONS: Serum IP-10 levels reflected UC disease activity, and the source of IP-10 was granulocytes and monocytes. Furthermore, serum IP-10 levels may be a marker for the responsiveness of patients to GMA treatment.
Authors: Konstantinos A Papadakis; John Prehn; Daocheng Zhu; Carol Landers; Joanne Gaiennie; Phillip R Fleshner; Stephan R Targan Journal: Inflamm Bowel Dis Date: 2004-11 Impact factor: 5.325
Authors: B S Boland; D L Boyle; W J Sandborn; G S Firestein; B G Levesque; J Hillman; B Zhang; J Proudfoot; L Eckmann; P B Ernst; J Rivera-Nieves; S Pola; N Copur-Dahi; J T Chang Journal: Aliment Pharmacol Ther Date: 2014-07-13 Impact factor: 8.171
Authors: S Hosomi; N Oshitani; N Kamata; M Sogawa; H Okazaki; T Tanigawa; H Yamagami; K Watanabe; K Tominaga; T Watanabe; Y Fujiwara; K Maeda; K Hirakawa; T Arakawa Journal: Clin Exp Immunol Date: 2010-11-19 Impact factor: 4.330
Authors: Farooq Z Rahman; Andrew M Smith; Bu'Hussain Hayee; Daniel J B Marks; Stuart L Bloom; Anthony W Segal Journal: PLoS One Date: 2010-03-26 Impact factor: 3.240
Authors: Amanda Waddell; Richard Ahrens; Yi-Ting Tsai; Joseph D Sherrill; Lee A Denson; Kris A Steinbrecher; Simon P Hogan Journal: J Immunol Date: 2013-04-05 Impact factor: 5.422
Authors: Ana Luisa Perdigoto; Thuy Tran; Natalie Patel; Pamela Clark; Kanchi Patell; Angeliki M Stamatouli; Vikram Reddy; James Clune; Kevan C Herold; Marie E Robert; Harriet M Kluger Journal: Clin Oncol Case Rep Date: 2020-09-17